1 October we become SureStone CapitalSame team, same ABN. Our website and email addresses move to surestone.com.au.
Preparing video
Paradigm Biopharmaceuticals (ASX:PAR) is aiming to address the significant unmet medical needs of osteoarthritis patients through the development of its lead drug candidate, Zilosul. Paul Rennie outlines the company’s progress, with Paradigm now halfway through a major phase three clinical trial involving 466 participants. Rennie states that extensive nonclinical and phase two clinical studies have ensured robust safety and efficacy data, with five separate phase two trials consistently demonstrating symptom relief and potential disease modification in osteoarthritis.
Rennie highlights the challenges faced by drug developers in moving from early-stage studies to successful late-stage trials, noting that Paradigm’s data supports a high probability of success through to a New Drug Application. The ongoing phase three study is set to reach a key milestone, with 50% of participants now recruited and an interim analysis expected to provide the first large-scale efficacy and safety assessment. This interim analysis is considered a critical value inflection point, drawing strong interest from potential commercial partners, especially as the pharmaceutical sector shifts towards licensing assets after late-stage results.
On the funding front, Rennie confirms Paradigm is fully funded through to the interim analysis, partly through arrangements with Obsidian. Management remains open to alternative funding sources to minimise shareholder dilution and support the company’s longer-term commercial strategy.
*paid partnership
